Hematology | Pfizer Medical Information

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Back to Diseases Areas

Oral Presentation

Lesokhin AM, Arnulf B, Nievizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 5, 2022 ASCO 2022 Hematology

Initial Safety Results for MagnetisMM-3: A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary

Poster

Lesokhin AM, Arnulf B, Niesvizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 10, 2022 EHA 2022 Hematology

A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Safety Results for MagnetisMM-3

View Presentation View Abstract Plain Language Summary

Poster

Montesinos P, Kota V, Brandwein J, Bousset P, Benner RJ, Vandendries E, McMullin MF June 10, 2022 EHA 2022 Hematology

A Phase 4 Study of Fractionated Gemtuzumab Ozogamicin on QT Interval and Safety in Patients With Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

View Presentation View Abstract Plain Language Summary

Poster

Cortes JE, Milojkovic D, Gambacorti-Passerini C, Garcia-Gutierrez V, Mauro MJ, Leip E, Purcell S, Viqueira A, Brummendorf TH June 10, 2022 EHA 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary

Poster

Russell-Smith A, Shah R, Silverstein AR, Petrilla A, Leinwand B, Norris D, Schroeder A June 10, 2022 EHA 2022 Hematology

Characteristics, Healthcare Utilization, and Costs Associated With Inotuzumab Ozogamicin, Blinatumomab, or Other Agents for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

View Presentation

Poster

Gambacorti-Passerini C, Brummendorf TH, Ernst T, Leip E, Purcell S, Viqueira A, Giles FJ, Rosti G, Hochhaus A June 10, 2022 EHA 2022 Hematology

Efficacy and Safety of Bosutinib in Later-Line Patients With Chronic Myeloid Leukemia: A Sub-Analysis From the Phase 4 BYOND Trial

View Presentation View Abstract Plain Language Summary

Poster

Dalovisio A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Chu MP, Gasparetto C, Sebag M, Lesokhin AM June 10, 2022 EHA 2022 Hematology

Updated Results From the Ongoing Phase 1 Study of Elranatamab, a BCMA Targeted T-Cell Redirecting Immunotherapy, for Patients With Relapsed or Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary

Poster

Deininger MW, Brummendorf TH, Lipton JH, Milojkovic D, Stenke L, Leip E, Purcell S, Viqueira A, Cortes JE December 10, 2022 ASH 2022 Hematology

Efficacy and Safety of Bosutinib Versus Imatinib by Charlson Comorbidity Index in Newly Diagnosed Patients With Chronic Myeloid Leukemia

View Presentation View Abstract Plain Language Summary

Oral Presentation

Bahlis N, Tomasson MH, Mohty M, Niesvizky R, Nooka A, Manier S, Maisel C, Jethava Y, Martinez-Lopez J, Prince HM, Arnulf B, Rodriguez-Otero P, Koehne G, Touzeau C, Raje N, Iida S, Raab M-S, Leip E, Sullivan S, Conte U, Viqueira A, Lesokhin A December 10, 2022 ASH 2022 Hematology

Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma Naïve to B-cell Maturation Antigen (BCMA)-Directed Therapies: Results From Cohort A of the MagnetisMM-3 Study

View Presentation View Abstract Plain Language Summary

Poster

Grosicki S, Mellqvist U-H, Pruchniewski L, Crafoord J, Trudel S, Min C-K, White D, Alegre A, Hansson M, Ikeda T, Sunami K, Leip E, Kudla A, Finn G, Koh Y December 10, 2022 ASH 2022 Hematology

Elranatamab in Combination With Daratumumab for Patients With Relapsed/Refractory Multiple Myeloma: Results From the Phase 3 MagnetisMM-5 Study Safety Lead-In Cohort

View Presentation View Abstract Plain Language Summary